Abstract: The present invention relates to the use of NSD3i inhibitors for the treatment of cancer. In particular, the present invention relates to methods, kits and compositions comprising NSD3 inhibitors to treat cancers dependent on NSD3, in particular subjects with NUT midline carcinoma (NMC) and subjects with NSD3/NUT or BRD4/NUT or BRD3/NUT fusion genes, as well as subjects with BRD4-dependent (but NUT-independent cancers). The present invention also relates to methods, kits and compositions comprising BET inhibitors for the treatment of subjects with NSD3/NUT fusion genes. Other aspects of the invention relate to assays and methods to identify an inhibitor of NSD3 which disrupts or decreases the interaction of the NSD3 protein with the ET do main of BRD4.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2ad/db protein, either directly or by gene transfer techniques, to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: The present invention relates to methods and reagents for targeting proteolysis of a polypeptide by cis or trans association with a ubiquitin protein ligase, and further provides methods and reagents for inhibiting the ubiquitination and proteolysis of cellular proteins which are recognized by a ubiquitin protein ligase.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2ad/db protein, either directly or by gene transfer techniques, to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2ad/db protein, either directly or by gene transfer techniques, to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: By virtue of the present invention, there is provided methods and compositions for interfering with the proliferation of cells infected and/or transformed by papillomaviruses. The processes and compositions of this invention may be used to treat any mammal, including humans. According to this invention, mammals are treated by the pharmaceutically acceptable administration of an E2 peptidomimetic to reduce the symptoms of the specific papillomavirus-associated disease, or to prevent their recurrence.

Abstract: The present invention provides compositions of isolated and purified E6 Associated Protein and fragments thereof. Also provided are nucleic acid constructs encoding E6 Associated Protein. These compositions may be employed to identify compounds which inhibit binding of high risk HPV E6 to p53. The compositions of the present invention may also be used in methods to detect the presence of high risk HPV in biological samples.

Abstract: Methods, kits, and compositions are provided for diagnosing papillomavirus infections by detecting the interaction between a papillomavirus E1 protein interaction domain and a papillomavirus E2 protein interaction domain.

Abstract: The present invention relates to improved models for progressive epithelial neoplasias and methods for their use. In particular, the invention provides transgenic mice comprising a human papilloma virus early region oncogene operably linked to a promoter which directs expression of the oncogene in a transient amplifying cell in the mice.

Abstract: The present invention provides compositions of isolated and purified E6 Associated Protein and fragments thereof. Also provided are nucleic acid constructs encoding E6 Associated Protein. These compositions may be employed to identify compounds which inhibit binding of high risk HPV E6 to p53. The compositions of the present invention may also be used in methods to detect the presence of high risk HPV in biological samples.

Abstract: A gene which is associated with tumor suppression and is localized on chromosome 11 has now been identified. The identification, localization and sequence of a gene which demonstrates differential expression in a manner that correlates with tumorigenicity suggests that this gene could potentially be used for gene therapy in cancers deleted or altered in their expression of the gene. Furthermore, a gene which is localized on chromosome 11p15, with identified polymorphisms, could be used for analysis of tumor DNA for loss of heterozygosity at chromosome 11p15. This region of chromosome 11 shows frequent loss of heterozygosity (LOH) in many human malignancies. Thus, the determination of LOH at chromosome 11p15 may be useful in predicting the prognosis of that tumor.

Abstract: A novel method and composition are provided for the replication and expression of exogenous genes in eukaryotic cells. A segment of a papilloma virus genome capable of extrachromosomal replication is linked to the foreign gene(s) using recombinant DNA techniques to provide a biologically functional replicon with a desired phenotypical property. The replicon is inserted into a eukaryotic cell by transformation, and the isolation of transformant provides cells for replication and expression of the DNA molecules present in the modified plasmid. The transforming region of the bovine papilloma virus provides a unique vector in that it provides both the capability of autonomous extrachromosomal replication but also the malignant transformed phenotype. Thus, genes which of themselves provide no selectable phenotypical property can be conveniently and efficiently introduced into eukaryotic cells and the transformants selected.